Daniel Tarquinio, DO
Neurology with Special Qualifications in Child Neurology · Gainesville, GANPI 1427131168
Payments from drug & device makers
Across 321 payments — averaging $1986.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$332K
- Ultragenyx Pharmaceutical Inc.$189K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$61K
- Takeda Pharmaceuticals U.S.A., Inc.$37K
- AbbVie$8K
- Acadia Pharmaceuticals Inc$3K
- plus $7K from 27 others
Across 10 payments — averaging $7229.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurelis, Inc.$68K
- Biogen$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 100 | $331,980 |
| Ultragenyx Pharmaceutical Inc. | 4 | $189,158 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 2 | $61,452 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $36,875 |
| AbbVie | 72 | $7,751 |
| Acadia Pharmaceuticals Inc | 18 | $2,954 |
| Cipla USA Inc. | 1 | $2,567 |
| Immedica Pharma US, Inc. | 3 | $2,318 |
| Pfizer | 36 | $524 |
| UCB, Inc. | 14 | $367 |
| SK Life Science, Inc. | 9 | $257 |
| Jazz Pharmaceuticals Inc. | 5 | $241 |
| Argenx US, Inc. | 7 | $174 |
| Teva Pharmaceuticals USA, Inc. | 7 | $162 |
| Novartis | 4 | $82 |
| Lilly USA, LLC | 4 | $77 |
| Eisai Inc. | 3 | $74 |
| PTC Therapeutics, Inc. | 1 | $66 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Biogen | 2 | $50 |
| Amneal Pharmaceuticals LLC | 3 | $49 |
| Kyowa Kirin, Inc. | 3 | $44 |
| Amgen | 2 | $41 |
| AstraZeneca | 2 | $34 |
| Abbott | 1 | $32 |
| Lundbeck LLC | 1 | $29 |
| Corium, LLC | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Catalyst Pharmaceuticals, Inc. | 1 | $26 |
| Johnson & Johnson | 1 | $23 |
| Boston Scientific | 1 | $20 |
| Bioventus LLC | 1 | $15 |
| Insightec,inc | 1 | $14 |
How this compares
$637,560 in reported general payments places this provider in the 90th percentile of 41 neurology with special qualifications in child neurology providers in Georgia.
See all neurology with special qualifications in child neurology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology with special qualifications in child neurology in Gainesville
- Han PhanAtlanta$16.4M
- John HemphillSavannah$4.9M
- Katherine MoretzSavannah$1.3M
- Chaouki KhouryAtlanta$1M
- Yong ParkAugusta$393K
- Sharlisa HutsonBrunswick$176K
- Stephanie KellerAtlanta$84K
- Lalitha SivaswamyMacon$59K
- Elizabeth SekulAugusta$57K
- Guojun ZhangAtlanta$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.